G2GBIO

G2GBIO, a company founded with the entrepreneurial spirit of Human First Respect for Life by Providing Good Medicines... G2GBIO's patented InnoLAMP technology excels in mass-producing uniform microsphere drug injectables with sustained release and high reproducibility. Suitable for peptides, small molecules, and various indications, it offers a cost-effective solution to meet global demand for high-quality, sustained-release drugs. We are committed to meeting global demand for cost-effective, sustained-release drug solutions with unparalleled quality and efficiency... For seven years since its inception in March 2017, G2GBIO has applied for 134 patents, including applications for 81 overseas individual countries and 18 PCT. To date, 52 applications were registered, including 43 international and 9 domestic patents, with the rest being pending or under review.

Also known as: G2GBIO, INC.